Tags

Type your tag names separated by a space and hit enter

Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue.
HIV Clin Trials. 2012 Mar-Apr; 13(2):103-10.HC

Abstract

OBJECTIVES

Whether zidovudine (AZT)-associated lipoatrophy occurrence differs by concomitant exposure to protease (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) remains unclear. Baseline body composition data from a randomized trial in subjects stable on first-line AZT-based therapy were used to explore this issue.

METHODS

In this substudy of the PREPARE trial, centrally read baseline whole-body dual energy x-ray aborptiometry (DXA) and single-slice abdominal CT scans were analyzed with respect to duration and type of prior AZT/lamivudine (3TC) combination antiretroviral therapy (cART), including by multivariate linear regression adjusted for age, gender, ethnicity, body mass index (BMI), and nadir CD4.

RESULTS

DXA and CT, from 134 and 136 patients, respectively [87% male; 82% Caucasian; mean (SD) age, 45.6 years (10); BMI, 24.3 kg/m² (3.2)], were analyzed. Prior AZT/3TC cART exposure was 5.5 (2.2) years. Seventy-eight and 27 patients had concomitantly and exclusively used NNRTIs and PIs, respectively. AZT/3TC cART, AZT/3TC/NNRTI, and AZT/3TC/PI, respectively, were associated with the presence of a mean (95% CI) of 247 g (-438 to -56; P = .012), 267 g (-467 to -66; P = .010), and 216 g (-430 to -1.7; P = .048) less baseline limb fat per additional year of prior exposure. Although abdominal subcutaneous (SAT) adipose tissue was likewise less with longer AZT/3TC cART, this was only significant for AZT/3TC/ NNRTI but not AZT/3TC/PI. Visceral adipose tissue (VAT) amount was not clearly associated to prior treatment. Increased age and male gender were independently associated with lower limb fat and SAT, but more VAT.

CONCLUSIONS

Longer exposure to AZT/3TC, regardless of whether in combination with PI or NNRTI, as well as increased age and male gender are independently associated with lower limb fat mass.

Authors+Show Affiliations

Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands. Saskia.Vrouenraets@siz.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22510357

Citation

Vrouenraets, S M E., et al. "Longer Prior Exposure to Zidovudine/lamivudine-containing Combination Antiretroviral Therapy, Age, and Male Gender Are Each Associated With Reduced Subcutaneous Adipose Tissue." HIV Clinical Trials, vol. 13, no. 2, 2012, pp. 103-10.
Vrouenraets SM, Wit FW, Garcia EF, et al. Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clin Trials. 2012;13(2):103-10.
Vrouenraets, S. M., Wit, F. W., Garcia, E. F., Huber, M., Brinkman, K., Moyle, G., Domingo, P., Tarr, P. E., Podzamczer, D., Ristola, M., Gatell, J. M., Livrozet, J. M., Furrer, H., & Reiss, P. (2012). Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clinical Trials, 13(2), 103-10. https://doi.org/10.1310/hct1302-103
Vrouenraets SM, et al. Longer Prior Exposure to Zidovudine/lamivudine-containing Combination Antiretroviral Therapy, Age, and Male Gender Are Each Associated With Reduced Subcutaneous Adipose Tissue. HIV Clin Trials. 2012 Mar-Apr;13(2):103-10. PubMed PMID: 22510357.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. AU - Vrouenraets,S M E, AU - Wit,F W N M, AU - Garcia,E Fernandez, AU - Huber,M, AU - Brinkman,K, AU - Moyle,G, AU - Domingo,P, AU - Tarr,P E, AU - Podzamczer,D, AU - Ristola,M, AU - Gatell,J M, AU - Livrozet,J M, AU - Furrer,H, AU - Reiss,P, AU - ,, PY - 2012/4/19/entrez PY - 2012/4/19/pubmed PY - 2012/6/6/medline SP - 103 EP - 10 JF - HIV clinical trials JO - HIV Clin Trials VL - 13 IS - 2 N2 - OBJECTIVES: Whether zidovudine (AZT)-associated lipoatrophy occurrence differs by concomitant exposure to protease (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) remains unclear. Baseline body composition data from a randomized trial in subjects stable on first-line AZT-based therapy were used to explore this issue. METHODS: In this substudy of the PREPARE trial, centrally read baseline whole-body dual energy x-ray aborptiometry (DXA) and single-slice abdominal CT scans were analyzed with respect to duration and type of prior AZT/lamivudine (3TC) combination antiretroviral therapy (cART), including by multivariate linear regression adjusted for age, gender, ethnicity, body mass index (BMI), and nadir CD4. RESULTS: DXA and CT, from 134 and 136 patients, respectively [87% male; 82% Caucasian; mean (SD) age, 45.6 years (10); BMI, 24.3 kg/m² (3.2)], were analyzed. Prior AZT/3TC cART exposure was 5.5 (2.2) years. Seventy-eight and 27 patients had concomitantly and exclusively used NNRTIs and PIs, respectively. AZT/3TC cART, AZT/3TC/NNRTI, and AZT/3TC/PI, respectively, were associated with the presence of a mean (95% CI) of 247 g (-438 to -56; P = .012), 267 g (-467 to -66; P = .010), and 216 g (-430 to -1.7; P = .048) less baseline limb fat per additional year of prior exposure. Although abdominal subcutaneous (SAT) adipose tissue was likewise less with longer AZT/3TC cART, this was only significant for AZT/3TC/ NNRTI but not AZT/3TC/PI. Visceral adipose tissue (VAT) amount was not clearly associated to prior treatment. Increased age and male gender were independently associated with lower limb fat and SAT, but more VAT. CONCLUSIONS: Longer exposure to AZT/3TC, regardless of whether in combination with PI or NNRTI, as well as increased age and male gender are independently associated with lower limb fat mass. SN - 1528-4336 UR - https://www.unboundmedicine.com/medline/citation/22510357/Longer_prior_exposure_to_zidovudine/lamivudine_containing_combination_antiretroviral_therapy_age_and_male_gender_are_each_associated_with_reduced_subcutaneous_adipose_tissue_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=22510357.ui DB - PRIME DP - Unbound Medicine ER -